Cambridge Bioscience has announced a new partnership with Cavidi, a leading Swedish biotech company specialising in reverse transcriptase-based technologies. Through this collaboration, Cambridge Bioscience will distribute Cavidi’s Exazym product range across the UK and Ireland, enhancing access to high-performance tools for virology and antiviral drug research.
Cavidi’s Exazym® is an add-on reagent that integrates seamlessly into existing immunoassay workflows. Utilising the proprietary Binding Oligo Ladder Detection (BOLD) method, Exazym® amplifies immunoassay signals by up to 100 times, enabling the detection of biomarkers at extremely low levels. Exazym® is compatible with standard laboratory instruments and protocols. It adds only one additional step to existing workflows, making it a practical solution for laboratories aiming to enhance their diagnostic capabilities.
This partnership strengthens Cambridge Bioscience’s offering in infectious disease research areas and supports Cavidi’s mission to make advanced virological tools more accessible to scientists worldwide. Learn more about Cavidi or contact our specialists.